Share price · GHRS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GHRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 26 Oct 2026+6.1%
Nothing announced by GHRS that day or the session before.
- 24 Sep 2026-5.8%
Nothing announced by GHRS that day or the session before.
- 16 Jul 2026+8.2%
Nothing announced by GHRS that day or the session before.
- 26 Jun 2026+11.4%
- 24 Apr 2026+7.7%
Nothing announced by GHRS that day or the session before.
- 22 Apr 2026-8.2%
Nothing announced by GHRS that day or the session before.
- 20 Apr 2026+17.2%
- 8 Jan 2026-13.4%
- 7 Jan 2026+27.1%
Nothing announced by GHRS that day or the session before.
- 6 Jan 2026-8.7%
Share of unusual movement by asset
For each asset, the share of GHRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Mebufotenin (5-MeO-DMT)(GH001) | Phase 2 | 5-HT2A receptorSmall molecule | Major Depressive Disorder |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | $11M | $250M | $14M-$14M operating cash flow | report ↗ |
GH Research reported no revenue for Q3 2025, with R&D spend of $10.57M, up 25.8% YoY from $8.4M. Cash and equivalents stood at $249.65M, and the company posted a net loss and quarterly net burn of $14.02M.
The company presented Phase 2b data for GH001, a synthetic mebufotenin inhalation therapy, in treatment-resistant depression. The trial met its primary endpoint, and secondary endpoints showed significant improvements in illness severity, anxiety symptoms, and quality of life at Day 8, with durable effects maintained at Month 6 in the open-label extension. No financial guidance was disclosed.
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | — | $9.0M | $254M | $9.3M-$9.0M operating cash flow | report ↗ |
| 2025-Q1 | — | $7.8M | $245M | $11M-$8.6M operating cash flow | report ↗ |
| 2024-Q3 | — | $8.4M | $90M | $12M-$12M operating cash flow | report ↗ |
| 2024-Q2 | — | $9.8M | $87M | $10M-$9.9M operating cash flow | report ↗ |
| 2024-Q1 | — | $8.7M | $77M | $7.7M-$9.6M operating cash flow | report ↗ |
| 2023-Q3 | — | $7.1M | $86M | $5.7M-$10M operating cash flow | report ↗ |
| 2023-Q2 | — | $7.2M | $97M | $7.7M-$8.0M operating cash flow | report ↗ |
| 2023-Q1 | — | $7.3M | $105M | $11M-$6.9M operating cash flow | report ↗ |
| 2022-Q3 | — | $4.6M | $257M | $0.4M-$8.0M operating cash flow | report ↗ |
| 2022-Q2 | — | $4.2M | $265M | — | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $39M | $246M | $12M-$44M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-08 | Schonharting Florian · director | Award / grant (derivative) | 2,303 | — | — | Form 4 |
| 2026-08-11 | Forer Michael · director | Award / grant (derivative) | 2,202 | — | — | Form 4 |
| 2026-08-11 | Hanley Dermot John · director | Award / grant (derivative) | 2,202 | — | — | Form 4 |
| 2026-08-11 | Moore Duncan · director | Award / grant (derivative) | 2,202 | — | — | Form 4 |
| 2026-08-11 | Forer Michael · director | Award / grant (derivative) | 100,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 53 reporting institutions held 47.6M shares ($668.5M, 76.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Lynx1 Capital Management LP | 10,763,288 | $151.3M |
| 2 | BVF INC/IL | 8,650,158 | $121.6M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 7,676,697 | $107.9M |
| 4 | RTW INVESTMENTS, LP | 5,933,815 | $83.4M |
| 5 | FMR LLC | 5,136,045 | $72.2M |
| 6 | Avoro Capital Advisors LLC | 1,800,000 | $25.3M |
| 7 | TORONTO DOMINION BANK | 1,397,873 | $19.7M |
| 8 | Troluce Capital Advisors LLC | 990,472 | $13.9M |
| 9 | MILLENNIUM MANAGEMENT LLC | 937,898 | $13.2M |
| 10 | Jefferies Financial Group Inc. | 712,300 | $10.0M |
| 11 | 5AM Venture Management, LLC | 572,665 | $8.1M |
| 12 | BlackRock, Inc. | 455,618 | $6.4M |
| 13 | UBS Group AG | 412,416 | $5.8M |
| 14 | Squadron Capital Management LLC | 325,000 | $4.6M |
| 15 | Foresite Capital Management VI LLC | 315,492 | $4.4M |